{
    "clinical_study": {
        "@rank": "78884", 
        "arm_group": [
            {
                "arm_group_label": "Ergoferon (1 tablet 3 times a day)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Oseltamivir (Tamiflu) - 1 capsule (75mg) two times a day", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is:\n\n        -  to assess efficiency of Ergoferon for treatment of influenza;\n\n        -  to assess safety of Ergoferon for treatment of influenza;\n\n        -  to compare efficiency of Ergoferon and Oseltamivir for treatment of influenza."
        }, 
        "brief_title": "Comparative Clinical Trial of Efficiency and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "The overall duration of a patient participation in the trial is 6 days\n      (screening/randomization/therapy onset - day 1; study therapy period - day 1-5;  follow-up\n      period - day 6)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients aged from 18 to 70 years inclusively.\n\n          2. Patients, who were admitted to hospital within 48 hours from the onset of influenza\n             signs.\n\n          3. Patients with body temperature \u226537,8\u00b0C when visiting a doctor + intensity of\n             influenza symptoms \u22654 score (presence of at least 1 general symptom \u22652 scores and 1\n             nasal/ throat/ chest symptom \u2265 2 scores or greater number of symptoms with the\n             intensity \u22651 score).\n\n          4. Diagnosed influenza confirmed by express diagnostics (OSOM Influenza A&B Test).\n\n          5. The possibility to start therapy within 48 hours after the onset of the first\n             symptoms of influenza.\n\n          6. Usage of contraceptive methods by both gender patients of reproductive age during the\n             trial and within 30 days after ending the participation in the trial.\n\n          7. Availability of signed patient information sheet (Informed Consent form) for\n             participation in the clinical trial.\n\n        Exclusion Criteria:\n\n          1. Suspected pneumonia.\n\n          2. Suspected initial manifestations of diseases that have symptoms similar to influenza\n             symptoms (other acute respiratory and infectious diseases, influenza-like syndrome at\n             the onset of systemic connective tissue disorders, oncohematology and other\n             pathology).\n\n          3. Patients requiring competitive antiviral drugs, which are prohibited during this\n             trial.\n\n          4. Medical history of primary and secondary immune deficiency: a) lymphoid system\n             immunodeficiency (T-cell and/or B-cell immunity chain, immunodeficiency with\n             predominant antibody deficiency); b) phagocyte deficiency; c) complement factors\n             deficiency; d) combined immunodeficiency including AIDS induced by HIV infection;\n             toxic, autoimmune, infectious, radial panleukopenia syndrome; general lymphocytopenia\n             syndrome; syndrome of lymphocyte polyclonal activation; postsplenectomia syndrome;\n             congenital asplenia; syndrome of immune complexes pathology associated with\n             infectious, allergic and autoimmune diseases.\n\n          5. Medical history of sarcoidosis.\n\n          6. Oncological disease/suspected oncological disease.\n\n          7. Exacerbation or decompensation of chronic diseases affecting the patient's  ability\n             to participate in the clinical trial.\n\n          8. Medical history of polyvalent allergy.\n\n          9. Allergy/ intolerance to any of the components of medications used in influenza\n             treatment.\n\n         10. Impaired glucose tolerance, type 1 and 2 diabetes mellitus.\n\n         11. Malabsorption syndrome, including congenital or acquired lactose deficiency or any\n             other disaccharide deficiency.\n\n         12. Exacerbation or decompensation of chronic diseases affecting patient's ability to\n             participate in the trial.\n\n         13. Pregnancy and breast feeding.\n\n         14. Drug addiction, alcohol usage in the amount exceeding 2 units of alcohol per day,\n             mental disorders.\n\n         15. Intake of medicines listed in the section \"Prohibited concomitant treatment\" for 1\n             month prior to the inclusion in the trial.\n\n         16. Patients, who from the investigator's point of view, will fail to comply with the\n             observation requirements of the trial or with the intake regimen of the investigated\n             medicines.\n\n         17. Participation in other clinical trials in the course of 1 month prior to the\n             inclusion in the trial.\n\n         18. Patient is related to the research personnel of the investigative site, who are\n             directly involved in the trial or are the immediate family member of the researcher.\n             The immediate family members includes husband/wife, parents, children or brothers (or\n             sisters), regardless of whether they are natural or adopted.\n\n         19. Patient works for OOO \"NPF \"Materia Medica Holding\" (i.e. is the company's employee,\n             temporary contract worker or appointed official responsible for the carrying out the\n             research) or the immediate relative.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850446", 
            "org_study_id": "MMH-ER-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ergoferon (1 tablet 3 times a day)", 
                "description": "Safety and Efficiency", 
                "intervention_name": "Ergoferon", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Oseltamivir (Tamiflu) - 1 capsule (75mg) two times a day", 
                "description": "Safety and Efficiency", 
                "intervention_name": "Oseltamivir", 
                "intervention_type": "Drug", 
                "other_name": "Tamiflu"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oseltamivir"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Petersburg", 
                    "country": "Russian Federation", 
                    "zip": "194044"
                }, 
                "name": "Federal State Budgetary Military Educational Institution of Higher Professional Education \"Military-Medicine Academy named after S. M. Kirov\" of Ministry of Defence of Russian Federation"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Parallel-group Randomized Clinical Trial of Efficiency and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Based on the results of objective examination conducted by a physician;\nRecovery criteria: body temperature \u226437.0\u00b0 C +  lack of symptoms; Improvement criteria: body temperature \u226437.2 \u00b0 C + total intensity of all symptoms (except for fever index) \u22642 scores.", 
            "measure": "Proportion of patient demonstrating recovery/ improvement  in health", 
            "safety_issue": "No", 
            "time_frame": "On day 2, 3, 4 and 5 of the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850446"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in body temperature on day 2, 3, 4 and 5 of the treatment in comparison with the baseline", 
                "measure": "Dynamics of fever", 
                "safety_issue": "No", 
                "time_frame": "On day 2, 3, 4 and 5 of the treatment"
            }, 
            {
                "description": "Criteria of no fever - body temperature lower than 37.0\u00b0 C for 24 hours", 
                "measure": "Average duration of fever", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "measure": "Proportion of patients with normal body temperature (no more than 37.0\u00ba\u0421)", 
                "safety_issue": "No", 
                "time_frame": "On day 2, 3, 4, 5 of the treatment"
            }, 
            {
                "description": "Based on the result of objective examination conducted by a physician", 
                "measure": "Severity of clinical manifestations of influenza (fever, general symptoms and nasal/ throat/ chest symptoms) in scores", 
                "safety_issue": "No", 
                "time_frame": "On day 1, 2, 3, 4 and 5 of the treatment"
            }, 
            {
                "description": "Based on the result of objective examination conducted by a physician", 
                "measure": "Duration of major clinical symptoms of influenza(fever, general symptoms and nasal/ throat/ chest symptoms) in days", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Based on the data on area under curve for total index of influenza severity; based on the results of objective examination conducted by a physician", 
                "measure": "The severity of influenza course", 
                "safety_issue": "No", 
                "time_frame": "On day 1, 2, 3, 4 and 5 of the treatment"
            }, 
            {
                "description": "Antipyretics, which are allowed for use during clinical trial, are:\nParacetamol;\nMetamizole sodium (if hyperthermia was not stopped by usage of paracetamol).", 
                "measure": "Quantity of antipyretics administration on day 1, 2, 3, 4 and 5 of the treatment", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 2, 3, 4 and 5 of the treatment"
            }, 
            {
                "measure": "Proportion of patients, who used antipyretics", 
                "safety_issue": "No", 
                "time_frame": "On day 1, 2, 3, 4 and 5 of the treatment"
            }, 
            {
                "measure": "Proportion of patients with the development of disease complications requiring antibiotics administration, and of patients with exacerbation of the disease course (the development of severe influenza)", 
                "safety_issue": "No", 
                "time_frame": "6 days"
            }, 
            {
                "description": "Based on the data on PCR of nasal sample", 
                "measure": "Proportion of patients with negative results of virology assay", 
                "safety_issue": "No", 
                "time_frame": "On day 3, 4, 5 and 6 of observation"
            }, 
            {
                "description": "Parameters of phagocytosis of peripheral blood macrophages (on day 1, 3 and 6 of observation);\nConcentration of regulators of T- cell immune response - IL2, IFN -\u03b3, IL-18 (on day 1,3 and 6 of observation) and regulators of \u0412-cellular antigen-specific immune response - IL-4, IL-16 (on day1, 3 and 6 of observation);\nLevel of leukocytes spontaneous and induced in vitro production of IFN-\u03b1 and IFN-\u03b3 (on day 1, 3 and 6 of observation);\nAbsolute count of leukocytes, absolute and relative count of neutrophils, lymphocytes, monocyte, eosinophils, basophils on day 1, 3 and 6 of observation;\nThe peculiarities of leukocyte phenotype in the dinamyc of the disease course - absolute and relative count of CD3, CD4, CD8, CD4/CD8; leukocyte CD16, CD119 (on day 1, 3 and 6 of observation).", 
                "measure": "Dynamics of parameters of immune status", 
                "safety_issue": "No", 
                "time_frame": "On day 1, 3 and 6 of observation"
            }
        ], 
        "source": "Materia Medica Holding", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Materia Medica Holding", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}